Headlines about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galectin Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.6343189974626 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern’s scoring:

GALT has been the subject of several recent analyst reports. Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 26th. ValuEngine lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $2.25.

Galectin Therapeutics (NASDAQ:GALT) traded up 1.16% during trading on Friday, hitting $1.74. The stock had a trading volume of 72,136 shares. The company’s market capitalization is $60.99 million. The stock’s 50-day moving average price is $1.96 and its 200-day moving average price is $2.28. Galectin Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Monday, August 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter in the prior year, the company posted ($0.20) earnings per share. Analysts expect that Galectin Therapeutics will post ($0.56) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/01/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-galectin-therapeutics-galt-share-price.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Stock Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related stocks with our FREE daily email newsletter.